Guillem Jose G, Moore Harvey G, Palmer Crystal, Glogowski Emily, Finch Rob, Nafa Khedoudja, Markowitz Arnold J, Offit Kenneth, Ellis Nathan A
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Fam Cancer. 2004;3(3-4):223-7. doi: 10.1007/s10689-004-0899-z.
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited colorectal cancer syndrome attributable to mutations in one of several DNA mismatch repair genes, most commonly MLH1 and MSH2 . In certain populations, founder mutations account for a substantial portion of HNPCC. In this report we summarize the literature and our personal experience testing for a specific founder mutation in the Ashkenazi Jewish population, MSH2*1906G > C , also known as A636P. Although rare in the general population, the A636P mutation is detected in up to 7% of Ashkenazi Jewish patients with early age-of-onset colorectal cancer, and may account for up to one third of HNPCC in the Ashkenazi Jewish population. In addition, we summarize our initial experience with a prospective A636P testing protocol aimed at Ashkenazi Jewish patients at high or intermediate risk for harboring the A636P mutation.
遗传性非息肉病性结直肠癌(HNPCC)是一种常染色体显性遗传的结直肠癌综合征,由几种DNA错配修复基因中的一种发生突变引起,最常见的是MLH1和MSH2。在某些人群中,始祖突变占HNPCC的很大一部分。在本报告中,我们总结了文献以及我们针对阿什肯纳兹犹太人群体中一种特定始祖突变MSH2*1906G > C(也称为A636P)进行检测的个人经验。尽管A636P突变在普通人群中很罕见,但在高达7%的患有早发性结直肠癌的阿什肯纳兹犹太患者中可检测到,并且可能占阿什肯纳兹犹太人群体中HNPCC的三分之一。此外,我们总结了我们针对有携带A636P突变高风险或中度风险的阿什肯纳兹犹太患者的前瞻性A636P检测方案的初步经验。